KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation
Paolo Lazzari,1 Marco Spiga,1 Monica Sani,1,2 Matteo Zanda,2,3 Ian N Fleming4 1KemoTech s.r.l., Parco Scientifico della Sardegna, Pula, Cagliari, 2C.N.R. – Istituto di Chimica del Riconoscimento Molecolare, Sezione ‘A. Quilico’, Milano, Italy; 3Kosterlitz Centre for The...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-05-01
|
Series: | Hypoxia |
Subjects: | |
Online Access: | https://www.dovepress.com/kemtub012-ni2-a-novel-potent-tubulysin-analog-that-selectively-targets-peer-reviewed-article-HP |